PNC-27
Very early researchGet notified when the evidence changes.
The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
A lab-designed peptide studied in cells for killing cancer cells. Very early research.
The basics
- What is it?
- PNC-27 joins a piece of the p53 protein to a short membrane-crossing tail. Most of what is published comes from cell studies, and the results are debated.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Not FDA approved and not on the U.S. compounding list. A doctor cannot prescribe it.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 5
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
No dosing information has been published in the research indexed here.
- Data from people, not a trialP53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.
Expert opinion on drug delivery · 2016
- Animal study, rats or miceTargeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
Leukemia · 2020
- Lab dish studyHDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.
Annals of clinical and laboratory science · 2025
- Lab dish studyKetone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.
Biomedicines · 2023
- Lab dish studyConjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: <i>In vitro</i> study.
Iranian journal of basic medical sciences · 2022
- Lab dish studyMolecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
Anticancer research · 2021
- Lab dish studyTargeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
Anticancer research · 2020
- Lab dish studyAnti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Annals of clinical and laboratory science · 2020
- Lab dish studySynergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
Annals of clinical and laboratory science · 2017
- Human tissue in a dish, not peopleEx vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
Annals of clinical and laboratory science · 2015
- Lab dish studyThe anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
Annals of clinical and laboratory science · 2014
- Lab dish studyAnti-cancer peptides from ras-p21 and p53 proteins.
Current pharmaceutical design · 2011
- Lab dish studyThe anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
Cancer chemotherapy and pharmacology · 2010
- Lab dish studyAnticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Proceedings of the National Academy of Sciences of the United States of America · 2010
- Lab dish studyThe penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
Annals of surgical oncology · 2008
- Lab dish studyNMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
Biochemistry · 2004
- Chemistry or materials paper, not a health studyThe role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.
Journal of molecular graphics & modelling · 2023
- Hypothesis, not a tested studyPNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Biomedicines · 2022
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
Annals of clinical and laboratory science · 2024
- Electronic structure and physicochemical properties characterization of the amino acids 12-26 of TP53: a theoretical study.
The journal of physical chemistry. A · 2007
- Review of earlier workPoptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.
Biomedicines · 2024
Spot an error? corrections@peptidesearch.org